Expression of HMGI(Y) proteins in squamous intraepithelial and invasive lesions of the uterine cervix.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 9458084.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The expression of nuclear proteins high mobility group (HMG) I and HMGY was investigated in intraepithelial and invasive lesions of the uterine cervix. Human carcinoma cell lines C-41, ME-180, and CaSki were used for testing protein expression in neoplastic cells from the cervix. Morphological grading of the dysplasias (CIN 1, CIN 2, and CIN 3) and invasive carcinomas from formalin-fixed paraffin-embedded samples parallels the degree of nuclear immunostaining obtained using a polyclonal antibody raised against the amino-terminal region of HMGI(Y) proteins. The immunostaining obtained with HMGI(Y) antibody was compared with that observed using the antibody Ki-67, and the results were similar. We suggest the use of HMGI(Y) antibody in clinical oncology as a useful marker of intraepithelial lesions and invasive carcinomas.
Medical subject headings
- Antigens, Neoplasm
- Biomarkers, Tumor
- Carcinoma, Squamous Cell
- High Mobility Group Proteins
- Uterine Cervical Neoplasms
- Uterine Cervical Dysplasia